NCT03987204View on ClinicalTrials.gov

Ivabradine for Rate Control in Permanent Atrial Fibrillation

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 15, 2019

Primary Completion Date

September 17, 2019

Study Completion Date

September 17, 2019

Conditions
Atrial FibrillationAtrial Fibrillation, Persistent
Interventions
DRUG

Ivabradine

Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.

Trial Locations (1)

06405

Yale New Haven Hospital, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT03987204 - Ivabradine for Rate Control in Permanent Atrial Fibrillation | Biotech Hunter | Biotech Hunter